New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 16, 2014
07:11 EDTMCO, WTW, GEVAHigh option volume stocks: MCO WTW GEVA XSP
News For MCO;WTW;GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
16:34 EDTGEVASynageva reports Q3 EPS ($1.46), consensus ($1.64)
Subscribe for More Information
10:34 EDTWTWOptions with decreasing implied volatility
Subscribe for More Information
10:18 EDTWTWWeight Watchers falls sharply, levels to watch
Subscribe for More Information
October 29, 2014
16:28 EDTWTWWeight Watchers raises FY14 adjusted EPS view to $1.95-$2.05 from $1.65-$1.85
Subscribe for More Information
16:26 EDTWTWWeight Watchers raises FY14 outlook
Subscribe for More Information
16:26 EDTWTWWeight Watchers reports Q3 EPS 67c, consensus 48c
Reports Q3 revenue $345.2M, consensus $337.52M.
October 28, 2014
08:30 EDTWTWWeight Watchers November volatility elevated into Q3 and outlook
Weight Watchers November call option implied volatility is at 83, December is at 59, January is at 52; compared to its 26-week average of 35 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on October 29.
07:22 EDTMCONYSSA to hold a conference
Subscribe for More Information
October 27, 2014
10:49 EDTMCOMoody's acquires Lewtan Technologies, terms not disclosed
Subscribe for More Information
October 24, 2014
07:10 EDTMCOMoody's reaffirms FY14 EPS view $3.95-$4.05, consensus $4.03
Subscribe for More Information
07:09 EDTMCOMoody's reports Q3 EPS 97c ex-items, consensus 90c
Subscribe for More Information
October 23, 2014
16:32 EDTGEVASynageva reports sebelipase alfa data at NASPGHAN meeting
Subscribe for More Information
15:39 EDTMCONotable companies reporting before tomorrow's open
Subscribe for More Information
09:40 EDTWTWWeight Watchers Q3 estimates meaningfully ahead of consensus at ITG Research
Subscribe for More Information
October 21, 2014
16:19 EDTGEVASynageva announces submission of BLA to the FDA for sebelipase
Synageva BioPharma announced the start of a rolling submission of a Biologics License Application, or BLA, to the FDA for sebelipase alfa as a treatment for patients with lysosomal acid lipase deficiency, a rare genetic disease with significant morbidity and early mortality. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The company anticipates completing the rolling submission of the BLA to the FDA and submitting the Marketing Authorization Application to the European Medicines Agency) by the end of January 2015.
09:48 EDTGEVAShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use